Home > Insider Trading > Filing (0001140361-17-046810)

Filing Details

Accession Number:: 0001140361-17-046810
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2017-12-19 19:47:31
Reporting Period:: 2017-12-15

Accepted Time:: 2017-12-19 19:47:31
Original Submission Date:: 2017-12-19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1012477	Avadel Pharmaceuticals Plc	AVDL	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1207106	R Craig Stapleton	Block 10-1, Blanchardstown Corporate Park, Ballycoolin Dublin L2 15		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Adss	Acquisiton	2017-12-15	70,000	$8.67	323,413	No	4	P	Direct
Adss	Acquisiton	2017-12-15	70,000	$8.67	180,000	No	4	P	Indirect	By Spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	By Spouse

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Adss	Warrants (right to buy)	$14.54	2015-06-24	2018-06-24	100,000	100,000	Direct
Adss	Warrants (right to buy)	$21.67	2016-06-26	2019-06-26	117,449	117,449	Direct
Adss	Warrants (right to buy)	$13.59	2017-08-10	2020-08-10	117,449	117,449	Direct
Adss	Stock Option (right to buy)	$10.51	2018-06-28	2022-06-28	30,000	30,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2018-06-24	100,000	100,000	Direct
2019-06-26	117,449	117,449	Direct
2020-08-10	117,449	117,449	Direct
2022-06-28	30,000	30,000	Direct

Footnotes

The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.45 to $8.75, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2).
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.45 to $8.75, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3).
The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities.
Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS.
Warrants were granted 06/26/2015 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS.
Warrants were granted 08/10/2016 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro) 12.16 per ADS. Warrants as to all 117,449 ADSs vested on 08/10/2017.
Options become exercisable as to all 30,000 ADSs on the first anniversary of the 06/28/2017 grant date.